• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by ResMed Inc.

    5/29/25 4:05:25 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email
    SD 1 d13023dsd.htm SD SD
     
     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM SD

     

     

    Specialized Disclosure Report

     

     

    ResMed Inc.

    (Exact Name of Registrant as Specified in Charter)

     

     

     

    Delaware   001-15317   98-0152841

    (State or Other Jurisdiction

    of Incorporation)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    9001 Spectrum Center Blvd.

    San Diego, California 92123

    (Address of Principal Executive Offices)

    Michael J. Rider

    (858) 836-5000

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended June 30, 2024.

     

     
     


    Section 1 - Conflict Minerals Disclosure

    Item 1.01 and Item 1.02 Conflict Minerals Disclosure and Report, Exhibits

    Conflict Minerals Disclosure

    This Form SD of ResMed Inc. is filed in accordance with Exchange Act Rule 13p-1, and covers the reporting period from January 1, 2024 through December 31, 2024.

    The description of our reasonable country of origin inquiry process, the results of our inquiry, and the determination we reached as a result of our reasonable country of origin inquiry process is included in our conflict minerals report attached as an exhibit to this Form SD. A copy of our conflict minerals report for the reporting period January 1, 2024 to December 31, 2024 is provided as Exhibit 1.01 and is available at www.resmed.com> For Investors > Corporate Governance > Corporate Governance Documents.

    Section 2 – Exhibits

    Item 2.01 Exhibits

    The following exhibit is filed as part of this report.

    Exhibit 1.01 – Conflict Minerals Report for the reporting period January 1, 2024 to December 31, 2024.

     

    2


    SIGNATURES

    We have authorized the person whose signature appears below to sign this report on our behalf, in accordance with the Securities Exchange Act of 1934.

     

    Date: May 29, 2025    

    RESMED INC.

    (registrant)

        By:  

    /s/ Michael J. Rider

        Name:   Michael J. Rider
        Its:   Global General Counsel & Secretary

     

    3

    Get the next $RMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    1/16/2025Buy
    Goldman
    1/10/2025$252.00Neutral
    Piper Sandler
    12/13/2024$250.00Hold
    Stifel
    9/24/2024$280.00Outperform
    Robert W. Baird
    9/18/2024$180.00Peer Perform → Underperform
    Wolfe Research
    9/4/2024Buy → Hold
    Needham
    More analyst ratings